Trials / Conditions / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

10 registered clinical trials studyying Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatmen NCT07007052	French Innovative Leukemia Organisation	Phase 2
Recruiting	CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial NCT06765876	Institute of Hematology and Blood Transfusion, Czech Republic	EARLY_Phase 1
Recruiting	Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmac NCT06006403	Chongqing Precision Biotech Co., Ltd	Phase 1 / Phase 2
Recruiting	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry NCT05430971	Immune Oncology Research Institute	—
Terminated	Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product NCT05645744	Mustang Bio	—
Terminated	Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. NCT04109482	Mustang Bio	Phase 1 / Phase 2
Active Not Recruiting	Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancie NCT04013685	Orca Biosystems, Inc.	Phase 1
Unknown	Combination Chemotherapy in Patients With Newly Diagnosed BPDCN NCT03599960	Centre Hospitalier Universitaire de Besancon	Phase 2
Terminated	Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN NCT03203369	Cellectis S.A.	Phase 1
Completed	Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia NCT02113982	Stemline Therapeutics, Inc.	Phase 1 / Phase 2